Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046321) TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046321 International Application No.: PCT/US2018/048375
Publication Date: 07.03.2019 International Filing Date: 28.08.2018
IPC:
G01N 33/574 (2006.01) ,A61K 39/00 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
BRISTOL-MYERS SQUIBB COMPANY [US/US]; Rt. 206 & Province Line Road Princeton, New Jersey 08543, US
Inventors:
KLIPPEL, Anke; US
MENARD, Laurence Celine; US
Agent:
KIM, Ji-Eun; US
BANOWIT, Donald R.; US
BEZOS, Salvador M.; US
BODENSTEIN, Matthew; US
CALVO, Paul A.; US
CAMARCE, Christian; US
CIMBALA, Michele A.; US
COLLER III, Richard D.; US
CONKLIN, Kyle; US
CORNWELL, David K.S.; US
COVERT, John M.; US
DURKIN, Tracy-Gene G.; US
EISENBERG, Jason D.; US
ELLISON, Eldora L.; US
ESMOND, Robert W.; US
FEATHERSTONE, Donald J.; US
FRUEAUF, Jeremiah B.; US
GAJEWSKI, Daniel; US
GILLENTINE, Marsha Rose; US
GOLDSTEIN, Jorge A.; US
HELVEY, Jeffrey T.; US
HICKS, Ross; US
HOLOUBEK, Michelle K.; US
JACKMAN, Peter A.; US
LEE, Michael Q.; US
LONGSWORTH, Gaby L.; US
MESSINGER, Michael V.; US
MILLONIG, Robert C.; US
MUTSCHELKNAUS, Joseph; US
NANNENGA-COMBS, Bonnie; US
POWERS III, R. Wilson; US
RAY, Michael B.; US
RYGIEL, Mark W.; US
SHEA JR., Timothy J.; US
SOKOHL, Robert E.; US
SPECHT, Michael D.; US
STEFFE, Eric K.; US
STERLING, Deborah A.; US
STERNE, Robert Greene; US
Priority Data:
62/551,13728.08.2017US
Title (EN) TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS
(FR) ANTAGONISTES DE TIM-3 POUR LE TRAITEMENT ET LE DIAGNOSTIC DE CANCERS
Abstract:
(EN) Provided herein are methods for treating a subject afflicted with a cancer, comprising administering to the subject a TIM3 agonist (e.g., an anti-TIM3 antibody), alone or in conjunction with another immune checkpoint inhibitor (e.g., a PD-1 antagonist), wherein the subject is identified as having a high frequency of TIM3 positive cells (e.g., on the tumor infiltrating inflammatory cells) or soluble TIM3 in peripheral blood. Also provided are methods for assessing the efficacy of a treatment comprising a TIM3 antagonist in a subject afflicted with a cancer, comprising measuring the frequency of TIM3 (and optionally PD-1) positive cells in certain populations of cells and/or the soluble TIM3 in peripheral blood of the subject, wherein a high frequency of TIM3 (and optionally PD-1) positive cells and/or the subject's peripheral blood titer of soluble TIM3 is indicative of the response to the treatment.
(FR) L'invention concerne des méthodes pour le traitement d'un sujet souffrant d'un cancer, comprenant l'administration au sujet d'un agoniste de TIM3 (par exemple un anticorps anti-TIM3), seul ou conjointement avec un autre inhibiteur des points de contrôle immunitaire (par exemple, un antagoniste de PD-1), le sujet étant identifié comme présentant une fréquence élevée de cellules positives pour TIM3 (par exemple sur les cellules inflammatoires infiltrant les tumeurs) ou de TIM3 soluble dans le sang périphérique. L'invention concerne également des procédés d'évaluation de l'efficacité d'un traitement comprenant un antagoniste de TIM3 chez un sujet souffrant d'un cancer, comprenant la mesure de la fréquence des cellules positives pour TIM3 (et éventuellement PD-1) dans certaines populations de cellules et/ou du TIM3 soluble dans le sang périphérique du sujet, une fréquence élevée de cellules positives pour TIM3 (et éventuellement PD-1) et/ou le titre du sang périphérique du sujet en TIM3 soluble étant révélateurs de la réponse au traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)